文献速递创伤骨科

罗莫索单抗治疗骨骼成熟成人新鲜单侧胫骨干骨折的随机2期研究

Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study.
PubMed 文献 · J Bone Joint Surg Am · 2020-01-01

这项双盲随机2期剂量探索试验将402例18至82岁胫骨干骨折手术固定患者按3:1:1:1:1:1:1:1:1:1随机分配至安慰剂组或9个罗莫索单抗组,术后皮下注射。主要结局影像学愈合时间在罗莫索单抗组为14.4至18.6周,安慰剂组为16.4周(95%CI:14.6至18.0周),无显著差异;临床愈合、非计划翻修手术、身体功能及安全性均与安慰剂相当。结论为罗莫索单抗未加速胫骨骨折愈合。

要点

  • 罗莫索单抗未显著缩短胫骨干骨折的影像学愈合时间。
  • 临床愈合时间、非计划翻修手术及身体功能均无显著治疗获益。
  • 安全性与耐受性与安慰剂相当,需在高延迟愈合风险人群进一步研究。

核心结论

  • 罗莫索单抗未加速该患者人群的胫骨骨折愈合。

研究设计与样本

  • 双盲、随机、2期、剂量探索试验,402例18至82岁胫骨干骨折手术固定患者随机分配至安慰剂或9个罗莫索单抗组。
  • 患者术后第1天及第2、6、12周接受皮下注射罗莫索单抗或安慰剂。

主要发现

  • 主要结局影像学愈合中位时间在罗莫索单抗组为14.4至18.6周,安慰剂组为16.4周(95%CI:14.6至18.0周),无显著差异。
  • 临床愈合中位时间无显著差异,罗莫索单抗剂量/频率与非计划翻修手术无关系,身体功能无 apparent 治疗获益。
  • 罗莫索单抗安全性与耐受性与安慰剂相当。

关键数值与推荐

  • 主要结局为影像学愈合时间,在所有患者第24周评估完成后分析。

临床怎么用

  • 基于本试验,罗莫索单抗不应常规用于加速胫骨干骨折手术后的愈合。
  • 对延迟愈合高风险患者,可考虑进一步研究探索罗莫索单抗的潜在作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Romosozumab is an antibody that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. A double-blinded, randomized, phase-2, dose-finding trial was performed to evaluate the effect of romosozumab on the radiographic and clinical outcomes of surgical fixation of tibial diaphyseal fractures. METHODS: Patients (18 to 82 years old) were randomized 3:1:1:1:1:1:1:1:1:1 to a placebo or 1 of 9 romosozumab treatment groups. Patients received subcutaneous injections of romosozumab or the placebo postoperatively on day 1 and weeks 2, 6, and 12. The primary outcome was the time to radiographic evidence of healing ("radiographic healing") analyzed after the week-24 assessments had been completed for all patients. RESULTS: A total of 402 patients were randomized: 299 to the romosozumab group and 103 to the placebo group. The median time to radiographic healing (the primary outcome) ranged from 14.4 to 18.6 weeks in the romosozumab groups and was 16.4 weeks (95% confidence interval [CI]: 14.6 to 18.0 weeks) in the placebo group, which was not a significant difference. There was also no significant difference in the median time to clinical healing, no relationship between romosozumab dose/frequency and unplanned revision surgery, and no apparent treatment benefit in terms of physical function. The safety and tolerability profile of romosozumab was comparable with that of the placebo. CONCLUSIONS: Romosozumab did not accelerate tibial fracture-healing in this patient population. Additional studies of patients at higher risk for delayed healing are needed to explore the potential of romosozumab to accelerate tibial fracture-healing. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Bhandari M, Schemitsch EH, Karachalios T, et al. Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study. J Bone Joint Surg Am. 2020. PMID: 32358413. doi:10.2106/JBJS.19.01008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。